The Contribution of Four Immunogenetic Markers for Predicting Persistent Activity in Patients with Recent-Onset Rheumatoid Arthritis or Undifferentiated Arthritis
Table 4
Univariate and multivariate linear analyses to identify predictors for disease activity score (DAS28) at one year.
Variablesa
Univariate Ξ² coeff. (95% CI)
value (Studentβs )
Multivariate Ξ² coeff. (95% CI)b
value (Studentβs )b
Anti-CCP (neg. versus pos.)
0.57 (0.20, 0.93)
0.003
β
β
RF (neg. versus pos.)
0.56 (0.18, 0.93)
0.004
β
β
SE (β/β versus β/+)
0.74 (0.36, 1.03)
<0.001
0.67 (0.32, 1.01)
<0.001
SE (β/β versus +/+)
0.83 (0.15, 1.51)
0.017
0.73 (0.11, 1.35)
0.021
β308 TNFΞ± (GA/AA versus GG)
0.01 (β0.46, 0.86)
0.980
β
β
Classification criteria (UA versus RA)
β0.29 (β0.31, 0.89)
0.342
β
β
Number of DMARD
0.66 (0.46, 0.86)
<0.001
0.63 (0.43, 0.82)
<0.001
Corticosteroids (yes versus. no)
β0.56 (β1.24, 0.15)
0.125
β
β
Linear regression equation
DAS28 at 1 year = 2.24 + 0.67 SE(β/+) + 0.73 SE(+/+) + 0.63 number of DMARDs
; ; .
a All variables measured at baseline, except classification criteria and treatments.
b Values not shown for variables not included in the model, that is, those with values β₯0.15. Abbreviations: CI: confidence interval. Anti-CCP: anticyclic citrullinated peptide antibodies. RF: rheumatoid factor. SE: shared epitope. β308 TNFΞ±: G-to-A polymorphism at position 308 of the TNFΞ± gene promoter. UA: undifferentiated arthritis. RA: rheumatoid arthritis. DMARD: disease-modifying antirheumatic drugs.